Xigris Related Published Studies
Well-designed clinical trials related to Xigris (Drotrecogin Alfa)
A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. [2008.01]
My brother has severe sepsis Should he receive Xigris(R)? [2007.12]
Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). [2007.09.01]
Drotrecogin alfa (activated) in the treatment of severe sepsis. [2007.09]
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. [2007.03.10]
Activated protein C (Xigris) treatment in sepsis: a drug in trouble. [2006.09]
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. [2005.09.29]
Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. [2005.03]
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. [2004.11]
Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis. [2004.09]
Effects of drotrecogin alfa (activated) in human endotoxemia. [2004.03]
[Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain] [2004.01]
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. [2004.01]
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. [2003.10]
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. [2003.09.15]
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. [2003.09]
Drotrecogin alfa (activated) treatment of older patients with severe sepsis. [2003.07.15]
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). [2003.07.01]
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. [2003.06]
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. [2003.03]
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. [2003.02]
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. [2003.01]
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. [2003.01]
Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. [2002.10]
Tamsulosin: an update of its role in the management of lower urinary tract symptoms. [2002]
Well-designed clinical trials possibly related to Xigris (Drotrecogin Alfa)
Current role of activated protein C therapy for severe sepsis and septic shock. [2008.09]
The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia. [2007.06]
RESOLVE-ing sepsis in children--not yet! [2007]
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. [2006]
Comment to: Septic shock: current pathogenic concept from a clinical perspective Tsiotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J Med Sci Monit, 2005; 11(3): RA76-RA85 Future treatment prespictives in septic shock. [2005.11.24]
Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. [2005]
Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. [2004.12]
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. [2004.11]
Evidence-based medicine in the ICU: important advances and limitations. [2004.08]
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. [2004.04]
Role of activated protein C in the pathophysiology of severe sepsis. [2003.11]
[Activated protein C--recent addition to therapy of sepsis] [2003.06.26]
Efficacy and safety of recombinant human activated protein C for severe sepsis. [2001.03.08]
Other research related to Xigris (Drotrecogin Alfa)
How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. [2008.10]
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis. [2008.09.11]
How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. [2008.05.27]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). [2008.04.04]
International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy. [2008.04]
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice. [2008.03]
A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study. [2008.01]
A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study. [2008.01]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). [2008]
Time-course of neopterin levels in patients suffering from severe sepsis treated with and without Drotrecogin-alpha (activated). [2008]
Drotrecogin alfa (activated): real-life use and outcomes for the UK. [2008]
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice. [2007.11.22]
Drotrecogin alpha (activated): the treatment for severe sepsis? [2007.11]
Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alpha (activated). [2007.09]
Effect of Drotrecogin alfa (activated) on platelet receptor expression in vitro. [2007.08]
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. [2007.06.25]
Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated). [2007.06.07]
ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation. [2007.06]
International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety. [2007.06]
ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis long-term follow-up: One-year safety and efficacy evaluation* [2007.04.20]
International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. [2007.04]
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. [2007.03]
Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. [2007.03]
The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant. [2007.03]
Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. [2007.01]
Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs. [2007.01]
Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis. [2007]
Practical aspects of treatment with drotrecogin alfa (activated). [2007]
The safety profile of drotrecogin alfa (activated). [2007]
Clinical trials in severe sepsis with drotrecogin alfa (activated). [2007]
From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated). [2006.12]
Drotrecogin alfa (activated) for nonmenstrual toxic shock syndrome associated with methicillin resistant Staphylococcus aureus infection. [2006.11]
International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. [2006.11]
Evaluation of drotrecogin alpha use in a Belgian university hospital. [2006.10]
Drotrecogin alfa (activated) in severe falciparum malaria. [2006.09]
Drotrecogin alfa (activated) in the treatment of severe sepsis. [2006.08]
Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. [2006.07]
Drotrecogin alpha (activated) in two patients with the hantavirus cardiopulmonary syndrome. [2006.07]
A case series of drotrecogin alfa (activated) in lung transplant recipients. [2006.06.27]
Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals. [2006.06.15]
[PROWESS, ENHANCE and ADDRESS: clinical implications for the treatment with drotrecogin alfa (activated)] [2006.06]
[Identification of surgical patients for therapy with activated Drotrecogin alfa] [2006.06]
International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH. [2006.05]
ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. [2006.05]
Estimate of the number of patients eligible for treatment with drotrecogin alfa (activated) based on differing international indications: post-hoc analysis of an inception cohort study in Australia and New Zealand. [2006.04]
Purpura fulminans during meningococcal sepsis treated with Drotrecogin alpha. A clinical case. [2006.04]
Use of drotrecogin alfa (activated) in older patients with severe sepsis. [2006.04]
Treatment of heparin-induced thrombocytopenia with drotrecogin alfa (activated). [2006.03]
[Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis] [2006.02.18]
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. [2006.01]
Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. [2006.01]
Use of drotrecogin alpha (recombinant human activated protein C, rhAPC) in the treatment of severe sepsis induced by graft pancreatitis after simultaneous pancreas and kidney transplantation: a case report. [2006.01]
Severe sepsis: patient management focusing on administration of drotrecogin alpha (activated) infusion. [2006.01]
Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. [2006]
Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? [2006]
Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. [2006]
Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. [2006]
Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes. [2005.11]
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated). [2005.10.05]
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. [2005.10]
A safety evaluation of drotrecogin alfa (activated) in hematopoietic stem cell transplant patients with severe sepsis: lessons in clinical research. [2005.10]
Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden. [2005.09]
Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis. [2005.08]
|
